Trial · NCT01176435

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

NCT01176435, Phase 2, Completed, University of Minnesota; results first posted 2018-05-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of L-DOPA as a Treatment to Improve Vision in Albinism. Trials, record NCT01176435. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01176435

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of L-DOPA as a Treatment to Improve Vision in Albinism
NCT number: NCT01176435
Status: Completed
Phases: Phase 2
Enrollment: 45 participants, actual
Lead sponsor: University of Minnesota
Conditions: Albinism
Interventions: Levodopa, Levodopa, Placebo
First posted: 2010-08-06
Last updated: 2018-05-02
Results first posted: 2018-05-02

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Improved Vision	20 weeks	Binocular best-corrected visual acuity-The visual acuity test is used to determine the smallest letters you can read on a standardized chart (Snellen chart) or a card held 20 feet (6 meters) away. Special charts are used when testing at distances shorter than 20 feet (6 meters). Ranges are 20/10 vision to 20/200 vision. 20/10 being the best and 20/200 being the worse.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Improved Vision	20 weeks		logMAR	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Improved Vision	0.76 mg/kg L-DOPA	0.67	95% Confidence Interval 0.20 to 1.0	logMAR
Improved Vision	0.51 mg/kg L-DOPA	0.55	95% Confidence Interval 0.20 to 0.88	logMAR
Improved Vision	Placebo	0.53	95% Confidence Interval 0.20 to 0.90	logMAR

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	0.76 mg/kg L-DOPA	15
Overall Study	STARTED	0.51 mg/kg L-DOPA	15
Overall Study	STARTED	Placebo	15
Overall Study	COMPLETED	0.76 mg/kg L-DOPA	15
Overall Study	COMPLETED	0.51 mg/kg L-DOPA	15
Overall Study	COMPLETED	Placebo	15
Overall Study	NOT COMPLETED	0.76 mg/kg L-DOPA	0
Overall Study	NOT COMPLETED	0.51 mg/kg L-DOPA	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events36

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	0.76 mg/kg L-DOPA	1	15	1
other	Headache	Nervous system disorders	0.51 mg/kg L-DOPA	2	15	2
other	Headache	Nervous system disorders	Placebo	0	15	0
other	Loss of Appetite	Gastrointestinal disorders	0.76 mg/kg L-DOPA	1	15	1
other	Loss of Appetite	Gastrointestinal disorders	0.51 mg/kg L-DOPA	1	15	1
other	Loss of Appetite	Gastrointestinal disorders	Placebo	1	15	1
other	Dizzy when standing quickly	Cardiac disorders	0.76 mg/kg L-DOPA	2	15	2
other	Dizzy when standing quickly	Cardiac disorders	0.51 mg/kg L-DOPA	0	15	0
other	Dizzy when standing quickly	Cardiac disorders	Placebo	1	15	1
other	Dry mouth	General disorders	0.76 mg/kg L-DOPA	2	15	2

1 to 10 of 36Source ClinicalTrials.gov

See all 36 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	0.76 mg/kg L-DOPA
Total, all-cause mortality	0.51 mg/kg L-DOPA
Total, all-cause mortality	Placebo
Total, other adverse events	0.76 mg/kg L-DOPA	11	15
Total, other adverse events	0.51 mg/kg L-DOPA	7	15
Total, other adverse events	Placebo	5	15
Total, serious adverse events	0.76 mg/kg L-DOPA	0	15
Total, serious adverse events	0.51 mg/kg L-DOPA	0	15
Total, serious adverse events	Placebo	0	15

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01176435

GET https://conductscience.org/api/trials/v1/NCT01176435/events?page=2

API reference For AI assistants